InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 191691

Sunday, 06/05/2016 12:42:41 PM

Sunday, June 05, 2016 12:42:41 PM

Post# of 346182

Looking at Dr. Martin Edelman for now...but first everyone should know, if one did not truly know... that Dr. Martin Edelman was a Bavituximab supporter and not saying he is not no longer, but we will soon find out.

Dr. Martin Edelman: "I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center

Dr. Edelman, Martin - post Part I

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92210261

Dr. Edelman, Martin - post Part II

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92435317&txt2find=martin|edelman



Dr. Edelman has had ties to working and collaborating and dozens of disclosures all leading back to Bristol Myers Squibb and it is now clear that SOMETHING forced Dr. Edelman into changing his mind to back off of working with Peregrine Pharmaceuticals and back into the Bristol Myers Squibb scene.... what would that be? This may be just one of many more puzzle pieces that will blow the lid off of how corrupt certain Big Pharma can be

Some don't think that it will go public and some are just collecting so much info that there will much more than enough info to make solid connections

https://clinicaltrials.gov/ct2/show/NCT00037089

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News